Ginger Extract Compared With Placebo in Adults With Asthma
Tests daily ginger extract against placebo in adults with asthma.
Plain-language title generated from the registry record
Registry title: Ginger's Therapeutic Potential in Asthma
Key facts
- Where
- New York, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Columbia University Asthma CenterNew York, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Emily DiMango, MD
- Trial code
- NCT07792395
- Record updated
- 28 August 2026
- Original description
Primary Objective: The primary endpoint is a clinically significant improvement in tolerance to inhaled methacholine (PD20).Read full original descriptionShow less
Ginger's Therapeutic Potential in Asthma - Phase 2a
Primary Objective: The primary endpoint is a clinically significant improvement in tolerance to inhaled methacholine (PD20).
Secondary Objectives: 1) To determine if oral daily ginger extract intake - decreases fractional excretion of nitric oxide; decreases blood eosinophilia; decreases asthma-associated cytokines in serum; decreases medium chain fatty acids; improves asthma symptoms; and 2) Establish pharmacokinetic parameters of biologically active components of ginger in adult asthmatics.
Inclusion: Adults aged 18 years or older with mild to severe persistent asthma as defined by NIH National Asthma Education and Prevention Program (NAEPP) guidelines, with asthma that is not optimally controlled despite current use of inhaled corticosteroids with or without inhaled long-acting beta agonists; Treatment with inhaled corticosteroids (ICS), with or without long-acting beta-agonists/long-acting muscarinic antagonists and montelukast; Physician-diagnosed asthma confirmed by history/report, pulmonary function testing with FEV1 ≥60% predicted or ≥1.5 L, and methacholine testing with baseline methacholine PD20 <16 mg/mL if taking ICS or <8 mg/mL if not taking ICS at Visit 2; Non-smoker of tobacco, e-cigarettes, or marijuana for ≥1 year. Nicotine patch or gum is permitted; Smoking history of ≤10 pack-years; Suboptimal asthma control as determined by an Asthma Control Test (ACT) score ≤19 at the Screening and Randomization Visits; Ability to understand English or Spanish, understand the study procedures, and comply with them f r the entire study period; Participants of childbearing potential must have negative urine pregnancy testing as required by the protocol and agree to use effective contraception during the trial.
Exclusion: Cardiovascular conditions including myocardial infarction or stroke within the previous 3 months, uncontrolled hypertension, or known aortic aneurysm; Oral corticosteroid use within the previous 6 weeks; Use of an investigational treatment within the previous 30 days; Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements; Major chronic illness that, in the judgment of the study physician, would interfere with study participation, including non-skin cancer, uncontrolled diabetes mellitus, coronary artery disease, congestive heart failure, stroke, severe hypertension, renal failure, liver disorders, malabsorption disorders, immunodeficiency states, major neuropsychiatric disorders, or seizure disorders; History of physician-diagnosed chronic bronchitis, emphysema, or COPD; Cancer other than skin cancer; Current use of ginger supplements; Use of anticoagulants, such as warfarin, rivaroxaban, or similar agents; Known adverse reaction to ginger or ginger products; Inability or unwillingness to provide written informed consent.